Metastatic Hormone Receptor-Positive Breast Cancer truly represents the frontier of Medical Oncology, with life expectancy creeping up to and beyond five years. This week, we discuss Monaleesa-2 (Ribociclib), Paloma-2 (Palbociclib) and, of course, highlight the importance of Monarch-3. The great CDK debate continues, and while the phase three trials have a clear winner, it's important to discuss the benefits and cons of each.

Studies discussed in the episode:

MONALEESA-2

PALOMA-2

MONARCH-3 (Mention)

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Hosted on Acast. See acast.com/privacy for more information.